Faye M. Johnson
YOU?
Author Swipe
View article: Stiefel MD Anderson OroPharynx cancer (MDA-OPC) cohort: a single-institution, prospective longitudinal outcomes study
Stiefel MD Anderson OroPharynx cancer (MDA-OPC) cohort: a single-institution, prospective longitudinal outcomes study Open
Purpose The MD Anderson Oropharynx Cancer (MDA-OPC) cohort is a unique single-institution, prospective longitudinal cancer cohort. The cohort aims to enhance the therapeutic index of OPC management by supporting data needs for independent …
View article: NOTCH1 Acts as a Tumor Suppressor That Induces Early Differentiation in Head and Neck Cancer
NOTCH1 Acts as a Tumor Suppressor That Induces Early Differentiation in Head and Neck Cancer Open
We identified frequent inactivating notch1 mutations in HNSCC over a decade ago, indicating its role as a tumor suppressor—unlike its oncogenic function in leukemias and salivary gland tumors. However, there has been much debate in the lit…
View article: Supplementary Table S4 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Table S4 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Table S4. Additional patient characteristics of HPV positive HNSCC patients.
View article: Supplementary Figure S9 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Figure S9 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Figure S9. Plasma concentrations of alisertib on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 7 (C1D7).
View article: Supplementary Figure S4 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Figure S4 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Figure S4. Gating strategy for flow cytometry analysis of PBMC.
View article: Supplementary Figure S2 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Figure S2 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Figure S2. Baseline and follow-up neck CT scans of a patient with recurrent metastatic squamous cell carcinoma.
View article: Supplementary Table S6 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Table S6 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Table S6. PK parameters for alisertib.
View article: Supplementary Figure S8 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Figure S8 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Figure S8. Changes in absolute lymphocyte count (ALC) from baseline to 6 weeks of therapy.
View article: Supplementary Figure S5 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Figure S5 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Figure S5. Flow cytometric analysis of PBMCs isolated from blood samples collected at baseline from the patients with PD or SD.
View article: Supplementary Table S1 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Table S1 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Table S1. Multiparametric 15-color flow cytometry panel used for analysis of human PBMCs, including Treg (CD4+Foxp3+), and functional markers for T cells (GrnzB, IFNγ, and PD-1).
View article: Supplementary Figure S1 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Figure S1 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Figure S1. Survival curves for phase 1 study patients based on Kaplan-Meier analysis.
View article: Supplementary Table S3 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Table S3 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Table S3. Representativeness of Study Participants.
View article: Supplementary Figure S3 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Figure S3 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Figure S3. Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS) in phase 2 patients, stratified by PD-L1 CPS score.
View article: Supplementary Table S2 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Table S2 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Table S2. Patient characteristics.
View article: Supplemental Methods S1 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplemental Methods S1 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplemental Methods S1
View article: Supplementary Figure S7 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Figure S7 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Figure S7. Flow cytometry analyses of circulating lymphocyte subsets in patients with acquired resistance (AR, n=8) or de novo resistance (DR, n=4) to prior anti-PD1 immunotherapy.
View article: Supplementary Figure S6 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Figure S6 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Figure S6. Plasma samples collected at the baseline from the participants of the trial were compared between the PD and SD groups of patients by the Luminex analyses to profile various cytokines and chemokines.
View article: Data from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Data from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Purpose:Effective therapy for recurrent head and neck squamous cell carcinoma (HNSCC) that is refractory to chemotherapy and immunotherapy is a considerable need. Aurora kinase A inhibition leads to apoptosis and immunogenic cell death in …
View article: Supplementary Table S5 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Supplementary Table S5 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Supplementary Table S5. Statistical comparisons of effector and suppressor immune cell populations in patients with de novo resistance (DR) and acquired resistance (AR) to anti-PD1 therapy.
View article: Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting
Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting Open
Background For patients with head and neck squamous cell carcinoma (HNSCC), failure of definitive radiation combined with cisplatin nearly universally results in death. Although hyperactivation of the Nrf2 pathway can drive radiation and c…
Targeted inhibition of Aurora kinase A promotes immune checkpoint inhibition efficacy in human papillomavirus-driven cancers Open
Background Human papillomavirus (HPV)-driven cancers include head and neck squamous cell carcinoma and cervical cancer and represent approximately 5% of all cancer cases worldwide. Standard-of-care chemotherapy, radiotherapy, and immune ch…
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas Open
Purpose: Effective therapy for recurrent head and neck squamous cell carcinoma (HNSCC) that is refractory to chemotherapy and immunotherapy is a considerable need. Aurora kinase A inhibition leads to apoptosis and immunogenic cell death in…
View article: Revisiting Feeding Tube Utilization in Oropharynx Cancer: 6‐Year Prospective Registry Analysis
Revisiting Feeding Tube Utilization in Oropharynx Cancer: 6‐Year Prospective Registry Analysis Open
Objective Patients treated for oropharyngeal cancer (OPC) have historically demonstrated high feeding tube rates for decreased oral intake and malnutrition. We re‐examined feeding tube practices in these patients. Study Design Retrospectiv…
View article: Supplementary Figure 2 from Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Supplementary Figure 2 from Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck Open
Pathologic response assessment